^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cisplatin/vinblastine/SHAO-FA (INT230-6)

    i
    Company:
    Intensity Therap
    Drug class:
    DNA synthesis inhibitor, Microtubule inhibitor, DNA cross linking agent, Apoptosis inhibitor
    Related drugs:
    Apply
    A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (KEYNOTE-A10) (NCT03058289)
    Phase 1/2
    Intensity Therapeutics, Inc.
    Completed
    Last update posted :
    08/13/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/22/2023
    Completion :
    02/22/2023
    MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)
    INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer (NCT04781725)
    Phase 2
    Ottawa Hospital Research Institute
    Recruiting
    Last update posted :
    11/17/2021
    Initiation :
    03/25/2021
    Primary completion :
    03/01/2022
    Completion :
    03/01/2023
    CD8 • CD4
    |
    cisplatin • cisplatin/vinblastine/SHAO-FA (INT230-6)